Literature DB >> 28123247

Anterior segment changes on ultrasound biomicroscopy after intravitreal anti vascular endothelial growth factor injection.

H S Trehan1, Jaya Kaushik2, Atul Rangi3, A S Parihar4, P Vashisht5, J K S Parihar6.   

Abstract

BACKGROUND: Intravitreal injections are standard of care today and have the potential to change the anatomy of the anterior segment of the eye. This research was undertaken to evaluate the changes in anterior segment anatomy after intravitreal anti vascular endothelial growth factor (anti VEGF) injections.
METHODS: We conducted a prospective interventional case series at a quaternary care center where patients undergoing intravitreal injection had pre and post injection ultrasound biomicroscopy (UBM) and intraocular pressure (IOP) measurement after intravitreal anti VEGF injection of 0.05 ml volume.
RESULTS: 75 eyes of 75 patients as per inclusion criteria were studied. A transient rise in IOP post intravitreal injection was found immediately after the injection. The mean rise from baseline was 17 mmHg immediately after injection and IOP returned to normal within 30 min in all cases. Angle measurement done as per established techniques revealed no significant changes in the angles and anterior chamber.
CONCLUSION: Intravitreal anti VEGF injections had no readily apparent short term concerns. IOP rise was transient and no case was found to have IOP high enough to cause concern for interruption of the optic nerve perfusion or statistically significant narrowing of the anterior chamber angle.

Entities:  

Keywords:  Anterior chamber; Anti vascular endothelial growth factor; Intraocular pressure; Intravitreal; Ultrasound biomicroscopy

Year:  2016        PMID: 28123247      PMCID: PMC5221393          DOI: 10.1016/j.mjafi.2016.10.007

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN: 0377-1237


  18 in total

Review 1.  Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer.

Authors:  Napoleone Ferrara; Kenneth J Hillan; Hans-Peter Gerber; William Novotny
Journal:  Nat Rev Drug Discov       Date:  2004-05       Impact factor: 84.694

2.  Short-term impact of intravitreal ranibizumab injection on axial ocular dimension and intraocular pressure.

Authors:  Altan Goktas; Sertan Goktas; Mustafa Atas; Suleyman Demircan; Yusufcan Yurtsever
Journal:  Cutan Ocul Toxicol       Date:  2012-06-27       Impact factor: 1.820

3.  Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab.

Authors:  S J Bakri; J S Pulido; C A McCannel; D O Hodge; N Diehl; J Hillemeier
Journal:  Eye (Lond)       Date:  2007-08-10       Impact factor: 3.775

4.  Short-term course of intraocular pressure after intravitreal injection of triamcinolone acetonide.

Authors:  Matthew S Benz; Thomas A Albini; Eric R Holz; Rohit R Lakhanpal; Andrew C Westfall; Mohan N Iyer; Petros E Carvounis
Journal:  Ophthalmology       Date:  2006-05-02       Impact factor: 12.079

5.  Ranibizumab for neovascular age-related macular degeneration.

Authors:  Philip J Rosenfeld; David M Brown; Jeffrey S Heier; David S Boyer; Peter K Kaiser; Carol Y Chung; Robert Y Kim
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

Review 6.  Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.

Authors:  Napoleone Ferrara; Lisa Damico; Naveed Shams; Henry Lowman; Robert Kim
Journal:  Retina       Date:  2006-10       Impact factor: 4.256

7.  Short-term effect of intravitreal injection of Ranibizumab (Lucentis) on intraocular pressure.

Authors:  Maurizio Gismondi; Carlo Salati; Maria L Salvetat; Marco Zeppieri; Paolo Brusini
Journal:  J Glaucoma       Date:  2009-12       Impact factor: 2.503

8.  Ultrasound biomicroscopy. II. Intraobserver and interobserver reproducibility of measurements.

Authors:  S F Urbak; J K Pedersen; T T Thorsen
Journal:  Acta Ophthalmol Scand       Date:  1998-10

9.  Tunnelled versus straight intravitreal injection: intraocular pressure changes, vitreous reflux, and patient discomfort.

Authors:  Pascal Bruno Knecht; Stephan Michels; Veit Sturm; Martina Monika Bosch; Marcel Nico Menke
Journal:  Retina       Date:  2009-09       Impact factor: 4.256

Review 10.  Ocular hypertension following intravitreal anti-vascular endothelial growth factor agents.

Authors:  Ravi S J Singh; Judy E Kim
Journal:  Drugs Aging       Date:  2012-12       Impact factor: 3.923

View more
  1 in total

1.  Paracentesis following intravitreal drug injections in maintaining physiologic ocular perfusion pressure.

Authors:  Austin Bach; Artur Filipowicz; Aaron S Gold; Azeema Latiff; Timothy G Murray
Journal:  Int J Ophthalmol       Date:  2017-12-18       Impact factor: 1.779

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.